---
title: "Induced pluripotent stem cells: from discovery to clinical translation"
id: "nature-0-induced-pluripotent-stem-cells-from-discovery-to-translation"
canonical_url: "https://medichelpline.com/clinical-feed/nature-0-induced-pluripotent-stem-cells-from-discovery-to-translation"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04584-3"
published_at: "2026-08-27T09:55:43.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Induced pluripotent stem cells: from discovery to clinical translation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-0-induced-pluripotent-stem-cells-from-discovery-to-translation
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04584-3)
- **Published At:** 2026-08-27T09:55:43.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Two decades after their discovery, **induced pluripotent stem cells (iPSCs)** have progressed from a basic biological finding into a clinical platform that can model human disease and inform therapies. - Progress reflects convergence of nonintegrating **cellular reprogramming**, robust differentiation protocols, advanced tissue engineering and precise **genome editing**, creating high-fidelity human cell–based systems. - These platform advances have supported the first wave of iPSC-based clinical trials and some recent early regulatory approvals, although specific trial or approval details were not reported in the source. - Major translational constraints include inherent biological variability in iPSC lines, manufacturing complexity for clinical-grade products and the need for long-term safety surveillance post‑translation. - The Review identifies operational barriers across the translational life cycle and outlines mitigation strategies spanning quality control, scalability and regulatory alignment (figures summarizing technologies, barriers and a 20-year outlook were included in the source). - The authors argue that integrating **automation** and **artificial intelligence** into iPSC workflows could enable scalable, standardized manufacturing and analytics, moving iPSC applications from bespoke models toward engineered biological medicines. - A forward-looking roadmap is presented that envisions continued technical maturation and system-level standardization over the next 20 years to facilitate broader clinical deployment. - Figures in the source illustrate (1) key enabling technologies for the iPSC platform, (2) barriers and mitigation strategies across the translational life cycle, and (3) a 20-year projection for iPSC technology and therapeutics.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04584-3#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04584-3) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ About the Editors ](https://www.nature.com/nm/editors) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [review articles](https://www.nature.com/nm/articles?type=review-article) 4. article * Review Article * Published: 27 August 2026 # Induced pluripotent stem cells from discovery to translation * [Jaecheol Lee](https://www.nature.com/articles/s41591-026-04584-3#auth-Jaecheol-Lee-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04584-3#Aff1),[2](https://www.nature.com/articles/s41591-026-04584-3#Aff2), * [Todd Herron](https://www.nature.com/articles/s41591-026-04584-3#auth-Todd-Herron-Aff3) [ORCID: orcid.org/0009-0000-3995-2306](https://orcid.org/0009-0000-3995-2306)[3](https://www.nature.com/articles/s41591-026-04584-3#Aff3), * [Lorenz Studer](https://www.nature.com/articles/s41591-026-04584-3#auth-Lorenz-Studer-Aff4) [ORCID: orcid.org/0000-0003-0741-7987](https://orcid.org/0000-0003-0741-7987)[4](https://www.nature.com/articles/s41591-026-04584-3#Aff4), * [Christine L. Mummery](https://www.nature.com/articles/s41591-026-04584-3#auth-Christine_L_-Mummery-Aff5) [ORCID: orcid.org/0000-0002-4549-6535](https://orcid.org/0000-0002-4549-6535)[5](https://www.nature.com/articles/s41591-026-04584-3#Aff5) & * … * [Joseph C. Wu](https://www.nature.com/articles/s41591-026-04584-3#auth-Joseph_C_-Wu-Aff1-Aff3) [ORCID: orcid.org/0000-0002-6068-8041](https://orcid.org/0000-0002-6068-8041)[1](https://www.nature.com/articles/s41591-026-04584-3#Aff1),[3](https://www.nature.com/articles/s41591-026-04584-3#Aff3) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04584-3#citeas) [ Save article ](https://www.nature.com/articles/s41591-026-04584-3/save-research?_csrf=VTPvLilVFGlT0FzIHQYuQ84MC_ckY7b5) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Two decades after the introduction of induced pluripotent stem cell (iPSC) technology, the field has evolved from a seminal biological discovery into a transformative clinical platform. This maturation reflects a convergence of nonintegrating cellular reprogramming, efficient differentiation protocols, high-fidelity tissue engineering and precise genome editing—which together have established a platform-level framework for recapitulating and probing human disease biology in human cell-based systems. While these milestones have enabled the first wave of iPSC-based therapeutic clinical trials and recent early approvals, the transition to standardized, widely deployable therapies remains constrained by inherent biological variability, manufacturing complexities and the need for long-term safety surveillance. This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development. Looking forward, we discuss how integrating automation and artificial intelligence could redefine iPSC workflows as scalable systems. We present a roadmap for the next 20 years, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological medicines. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04584-3) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04584-3) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue [Learn more](https://www.nature.com/nm/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04584-3) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Key technologies for building the iPSC platform and their translational impact.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04584-3/MediaObjects/41591_2026_4584_Fig1_HTML.png) **Fig. 2: Barriers and mitigation strategies across the translational life cycle of iPSC-derived therapeutics.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04584-3/MediaObjects/41591_2026_4584_Fig2_HTML.png) **Fig. 3: The next 20 years of iPSC-based technology and therapeutics.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04584-3/MediaObjects/41591_2026_4584_Fig3_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [History](https://www.nature.com/subjects/history) * [Induced pluripotent stem cells](https://www.nature.com/subjects/induced-pluripotent-stem-cells) ## References 1. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. _Cell_ **126** , 663–676 (2006). [Article](https://doi.org/10.1016%2Fj.cell.2006.07.024) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xpt1aktbs%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16904174) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Induction%20of%20pluripotent%20stem%20cells%20from%20mouse%20embryonic%20and%20adult%20fibroblast%20cultures%20by%20defined%20factors&journal=Cell&doi=10.1016%2Fj.cell.2006.07.024&volume=126&pages=663-676&publication_year=2006&author=Takahashi%2CK&author=Yamanaka%2CS) 2. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. _Cell_ **131** , 861–872 (2007). [Article](https://doi.org/10.1016%2Fj.cell.2007.11.019) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2sXhsVCntbbK) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18035408) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Induction%20of%20pluripotent%20stem%20cells%20from%20adult%20human%20fibroblasts%20by%20defined%20factors&journal=Cell&doi=10.1016%2Fj.cell.2007.11.019&volume=131&pages=861-872&publication_year=2007&author=Takahashi%2CK) 3. Lancaster, M. A. & Knoblich, J. A. Organogenesis in a dish: modeling development and disease using organoid technologies. _Science_ **345** , 1247125 (2014). [Article](https://doi.org/10.1126%2Fscience.1247125) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25035496) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Organogenesis%20in%20a%20dish%3A%20modeling%20development%20and%20disease%20using%20organoid%20technologies&journal=Science&doi=10.1126%2Fscience.1247125&volume=345&publication_year=2014&author=Lancaster%2CMA&author=Knoblich%2CJA) 4. Clevers, H. Modeling development and disease with organoids. _Cell_ **165** , 1586–1597 (2016). [Article](https://doi.org/10.1016%2Fj.cell.2016.05.082) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVWlurvN) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27315476) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Modeling%20development%20and%20disease%20with%20organoids&journal=Cell&doi=10.1016%2Fj.cell.2016.05.082&volume=165&pages=1586-1597&publication_year=2016&author=Clevers%2CH) 5. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. _Cell_ **146** , 318–331 (2011). [Article](https://doi.org/10.1016%2Fj.cell.2011.06.019) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXptlekt7w%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21757228) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155290) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Generation%20of%20isogenic%20pluripotent%20stem%20cells%20differing%20exclusively%20at%20two%20early%20onset%20Parkinson%20point%20mutations&journal=Cell&doi=10.1016%2Fj.cell.2011.06.019&volume=146&pages=318-331&publication_year=2011&author=Soldner%2CF) 6. Neavin, D. R. et al. A village in a dish model system for population-scale hiPSC studies. _Nat. Commun._ **14** , 3240 (2023). [Article](https://doi.org/10.1038%2Fs41467-023-38704-1) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXht1amu7bE) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37296104) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256711) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20village%20in%20a%20dish%20model%20system%20for%20population-scale%20hiPSC%20studies&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-023-38704-1&volume=14&publication_year=2023&author=Neavin%2CDR) 7. Wells, M. F. et al. Natural variation in gene expression and viral susceptibility revealed by neural progenitor cell villages. _Cell Stem Cell_ **30** , 312–332 (2023). [Article](https://doi.org/10.1016%2Fj.stem.2023.01.010) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXjt12gsbs%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36796362) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581885) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Natural%20variation%20in%20gene%20expression%20and%20viral%20susceptibility%20revealed%20by%20neural%20progenitor%20cell%20villages&journal=Cell%20Stem%20Cell&doi=10.1016%2Fj.stem.2023.01.010&volume=30&pages=312-332&publication_year=2023&author=Wells%2CMF) 8. Kang, H. M. et al. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. _Nat. Biotechnol._ **36** , 89–94 (2018). [Article](https://doi.org/10.1038%2Fnbt.4042) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvFGmur3F) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29227470) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Multiplexed%20droplet%20single-cell%20RNA-sequencing%20using%20natural%20genetic%20variation&journal=Nat.%20Biotechnol.&doi=10.1038%2Fnbt.4042&volume=36&pages=89-94&publication_year=2018&author=Kang%2CHM) 9. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S. & Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. _Am. Heart J._ **167** , 292–300 (2014). [Article](https://doi.org/10.1016%2Fj.ahj.2013.11.004) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24576511) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Rechanneling%20the%20cardiac%20proarrhythmia%20safety%20paradigm%3A%20a%20meeting%20report%20from%20the%20Cardiac%20Safety%20Research%20Consortium&journal=Am.%20Heart%20J.&doi=10.1016%2Fj.ahj.2013.11.004&volume=167&pages=292-300&publication_year=2014&author=Sager%2CPT&author=Gintant%2CG&author=Turner%2CJR&author=Pettit%2CS&author=Stockbridge%2CN) 10. Yamazaki, D. et al. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes. _J. Pharmacol. Sci._ **136** , 249–256 (2018). [Article](https://doi.org/10.1016%2Fj.jphs.2018.02.005) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXktlSqsL4%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29555184) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Proarrhythmia%20risk%20prediction%20using%20human%20induced%20pluripotent%20stem%20cell-derived%20cardiomyocytes&journal=J.%20Pharmacol.%20Sci.&doi=10.1016%2Fj.jphs.2018.02.005&volume=136&pages=249-256&publication_year=2018&author=Yamazaki%2CD) 11. Blinova, K. et al. International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. _Cell Rep._ **24** , 3582–3592 (2018). [Article](https://doi.org/10.1016%2Fj.celrep.2018.08.079) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhslyqtr7I) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30257217) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226030) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=International%20multisite%20study%20of%20human-induced%20pluripotent%20stem%20cell-derived%20cardiomyocytes%20for%20drug%20proarrhythmic%20potential%20assessment&journal=Cell%20Rep.&doi=10.1016%2Fj.celrep.2018.08.079&volume=24&pages=3582-3592&publication_year=2018&author=Blinova%2CK) 12. Strauss, D. G. et al. Comprehensive in vitro Proarrhythmia Assay (CiPA) update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA meeting. _Ther. Innov. Regul. Sci._ **53** , 519–525 (2019). [Article](https://doi.org/10.1177%2F2168479018795117) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30157676) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Comprehensive%20in%20vitro%20Proarrhythmia%20Assay%20%28CiPA%29%20update%20from%20a%20Cardiac%20Safety%20Research%20Consortium%20%2F%20Health%20and%20Environmental%20Sciences%20Institute%20%2F%20FDA%20meeting&journal=Ther.%20Innov.%20Regul.%20Sci.&doi=10.1177%2F2168479018795117&volume=53&pages=519-525&publication_year=2019&author=Strauss%2CDG) 13. de Korte, T. et al. Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell-derived cardiomyocytes: fit for purpose or forever elusive? _Annu. Rev. Pharmacol. Toxicol._ **60** , 529–551 (2020). [Article](https://doi.org/10.1146%2Fannurev-pharmtox-010919-023309) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31506008) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Unlocking%20personalized%20biomedicine%20and%20drug%20discovery%20with%20human%20induced%20pluripotent%20stem%20cell-derived%20cardiomyocytes%3A%20fit%20for%20purpose%20or%20forever%20elusive%3F&journal=Annu.%20Rev.%20Pharmacol.%20Toxicol.&doi=10.1146%2Fannurev-pharmtox-010919-023309&volume=60&pages=529-551&publication_year=2020&author=Korte%2CT) 14. Gintant, G. et al. Repolarization studies using human
## Related Clinical Research

- [Genomic analyses support managing Acropora cervicornis as a single conservation unit across the Ca](https://medichelpline.com/clinical-feed/biorxiv-19-limited-neutral-and-adaptive-genomic-divergence-suggests-acropora-cervicornis.md)
- [Measuring Rearrangement Complexity in Pangenomes with the CARP Framework](https://medichelpline.com/clinical-feed/biorxiv-5-quantifying-the-rearrangement-complexity-of-pangenomes.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)
- [Emergency diagnosis frequency and outcomes across 13 non-cancer conditions in England: analysis of](https://medichelpline.com/clinical-feed/plos-medicine-2-frequency-and-prognostic-outcomes-of-emergency-diagnosis-in-13-non-neoplastic.md)
- [Coffee consumption associated with lower visceral fat, higher muscle mass, and hormonal differences](https://medichelpline.com/clinical-feed/medical-news-today-0-coffee-drinking-linked-to-less-abdominal-fat-more-muscle-better-hormone-balance.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.